I.b

Pneumonitis (ILD)

Or 'ILD'. (Fr: PnP subaiguë). A.k.a. pulmonary infiltrates. Generally bilateral and symmetrical. Gradual onset. Consistent with but not specific for an NSIP-c pattern on pathology. Less- dense, severe, acute and diffuse than pattern Ia. Lacks the features of ARDS that may accompany pattern Ia. Can be in the form of disseminated linear, reticulonodular, miliary or patchy opacities. BAL is indicated to separate this pattern from PIE (Ic) or DAH (IIIa). Acute chest pain can be at the forefront. A search for microorganisms including Pneumocystis (stains, PCR) is indicated. On pathology (although not many cases undergo a confirmatory lung biopsy), there is interstitial inflammation and a more or less dense cellular interstitial cellular infiltrate (NSIP-c). Fibrosis, alveolar edema and/or a reactive epithelium denote those cases resulting from with antineoplastic chemotherapy agents. The frontier between patterns Ia and I b can be difficult to draw, so please check drugs under both Ia and Ib. Patients may quickly shift from pattern Ib to Ia particularly if the the causal drug is inappropriately continued. Prompt withdrawal must be considered, underlying disease permitting, and can be therapeutic.

Last update : 01/01/1970
 

Causative drugs

403

Abemaciclib

3

Abiraterone

1

Acebutolol

1

Acyclovir

1

Adagrasib

1

Adalimumab

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis I.m I - Interstitial/parenchymal lung disease
I.m - ILD with a granulomatous component I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome) I.z I - Interstitial/parenchymal lung disease
I.z - An area or areas of consolidation II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH) III.d III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.d - Alveolar hemorrhage, diffuse (ANCA-positive/-related) IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus) V.m V - Pleural and/or pericardial involvement
V.m - Pleuropericarditis - Pleuropericardial effusion (ANA unknown or negative) IX.j IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.j - Phrenic nerve injury - Hemi- or bilateral diaphragmatic paralysis X.b X - Systemic/Distant conditions, syndromes and reactions
X.b - Antiphospholipid antibodies w/wo the APL syndrome X.e X - Systemic/Distant conditions, syndromes and reactions
X.e - Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs) X.j X - Systemic/Distant conditions, syndromes and reactions
X.j - Myopathy-Myositis-Polymyositis (see also under Xba) X.k X - Systemic/Distant conditions, syndromes and reactions
X.k - Sarcoid-like granulomatosis (endo-/extrathoracic) X.s X - Systemic/Distant conditions, syndromes and reactions
X.s - Vasculitis, pulmonary (w/wo AH), extrapulmonary, systemic: ANCA-positive XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib) XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id) XV.e XV - Pathology
XV.e - Path: ILD with a granulomatous component (see also Im) XVI.k XVI - Imaging
XVI.k - Imaging: An area or areas of consolidation XVII.a XVII - Infections & related conditions
XVII.a - Respiratory tract infection incl. pneumonia XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infections XVII.c XVII - Infections & related conditions
XVII.c - Aspergillosis, pulmonary (invasive, allergic [ABPA], or mycetoma) XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia XVII.f XVII - Infections & related conditions
XVII.f - Tuberculosis, miliary XVII.g XVII - Infections & related conditions
XVII.g - Tuberculosis (pulmonary, pulmonary, extrapulmonary or disseminated). Reactivation or de novo XVII.z XVII - Infections & related conditions
XVII.z - Histoplamosis (reactivation) XVII.aa XVII - Infections & related conditions
XVII.aa - Coccidioidomycosis
1

Afatinib

1

Albuferon (albinterferon)

2

Alectinib

1

Alemtuzumab

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) II.a II - Pulmonary edema - Acute lung injury - ARDS
II.a - Pulmonary edema, noncardiogenic (NCPE) II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH) IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma VI.b VI - Pulmonary vasculopathies
VI.b - Pulmonary arterial hypertension X.e X - Systemic/Distant conditions, syndromes and reactions
X.e - Autoimmunity-Autoimmune conditions (+ANA, +anti-ds-DNA, +ANCAs, other auto-Abs) X.g X - Systemic/Distant conditions, syndromes and reactions
X.g - Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement) X.k X - Systemic/Distant conditions, syndromes and reactions
X.k - Sarcoid-like granulomatosis (endo-/extrathoracic) X.ac X - Systemic/Distant conditions, syndromes and reactions
X.ac - Anti-GBM antibody disease (Goodpasture-like or flare of preexisting GS) X.an X - Systemic/Distant conditions, syndromes and reactions
X.an - Cytokine release syndrome - Cytokine storm XIII.b XIII - Neoplastic conditions
XIII.b - Lymphoproliferative disease (pulmonary, endobronchial, endothoracic) XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib) XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL) XVII.b XVII - Infections & related conditions
XVII.b - Opportunistic pulmonary/systemic infections XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia XVII.h XVII - Infections & related conditions
XVII.h - Nontuberculous pulmonary mycobacterial infection/superinfection
1

Alk inhibitors

2

Alkylating agents

4

All-transretinoic acid (ATRA)

1

Almonertinib

1

Amikacin (inhaled-, liposomal-)

1

Amiodarone

I.a I - Interstitial/parenchymal lung disease
I.a - Pneumonitis (ILD), acute and/or severe (may cause ARDS) I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) I.d I - Interstitial/parenchymal lung disease
I.d - Organizing pneumonia pattern (an area or areas of consolidation on imaging) I.e I - Interstitial/parenchymal lung disease
I.e - Acute eosinophilic pneumonia (AEP) I.f I - Interstitial/parenchymal lung disease
I.f - Acute fibrinous organizing pneumonia (AFOP) I.g I - Interstitial/parenchymal lung disease
I.g - Pulmonary fibrosis I.h I - Interstitial/parenchymal lung disease
I.h - Subclinical pulmonary infiltrates/ILD I.k I - Interstitial/parenchymal lung disease
I.k - Lung nodule or nodules I.l I - Interstitial/parenchymal lung disease
I.l - Diffuse alveolar damage (DAD) (see alsoo under IIb and XVf) I.s I - Interstitial/parenchymal lung disease
I.s - A mass or masses I.u I - Interstitial/parenchymal lung disease
I.u - Relapsing or migrating pneumonitis/pneumonia (see also Id) I.w I - Interstitial/parenchymal lung disease
I.w - Rapidly progressive ILD/pulmonary fibrosis (Hamman-Rich syndrome) I.z I - Interstitial/parenchymal lung disease
I.z - An area or areas of consolidation I.aa I - Interstitial/parenchymal lung disease
I.aa - Delayed ILD, -pneumonitis, -fibrosis I.ao I - Interstitial/parenchymal lung disease
I.ao - Pulmonary infiltrates I.at I - Interstitial/parenchymal lung disease
I.at - Amiodarone pulmonary toxicity - Amiodarone lung I.ax I - Interstitial/parenchymal lung disease
I.ax - Chronic pneumonitis I.ay I - Interstitial/parenchymal lung disease
I.ay - Unilateral interstitial lung disease II.b II - Pulmonary edema - Acute lung injury - ARDS
II.b - ARDS - Acute lung injury II.l II - Pulmonary edema - Acute lung injury - ARDS
II.l - Postoperative ARDS III.a III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.a - Alveolar hemorrhage (AH), diffuse AH (DAH) III.c III - Pulmonary/alveolar./airway hemorrhage/bleeding
III.c - Hemoptysis IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma IV.d IV - Airway involvement
IV.d - Cough (lone) IV.r IV - Airway involvement
IV.r - Airway pigmentation (black, bluish, petechial) V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion (uni- or bilateral) (can accompany DI-LDs) V.c V - Pleural and/or pericardial involvement
V.c - Pleural thickening V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus) V.t V - Pleural and/or pericardial involvement
V.t - The apical cap VI.a VI - Pulmonary vasculopathies
VI.a - Pulmonary embolism - Venous thrombosis/thromboembolism VI.i VI - Pulmonary vasculopathies
VI.i - Acute pulmonary hypertension VIII.a VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.a - Angioedema (may cause UAO, asphyxia and death) IX.a IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.a - Diaphragm/inspiratory muscle weakness/paralysis (w/wo ARF) IX.d IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.d - Respiratory failure from ventilatory depression (due to neuromuscular blockade/paralysis) IX.ai IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.ai - Acute respiratory failure (hypoxemia, acidosis) from myxedema (-coma) X.d X - Systemic/Distant conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd) X.f X - Systemic/Distant conditions, syndromes and reactions
X.f - Anaphylaxis-Anaphylactoid reaction (can be fatal) X.q X - Systemic/Distant conditions, syndromes and reactions
X.q - Systemic inflammatory response XI.c XI - Miscellaneous
XI.c - Pleuritic chest pain XI.f XI - Miscellaneous
XI.f - Bluish, pseudocyanotic skin discoloration XI.bq XI - Miscellaneous
XI.bq - Platypnea-orthodeoxia XII.a XII - Cardiovascular involvement / toxicity
XII.a - Left or biventricular dysfunction/failure XII.c XII - Cardiovascular involvement / toxicity
XII.c - Pericardial effusion (w/wo tamponade) XII.e XII - Cardiovascular involvement / toxicity
XII.e - Takotsubo (stress) cardiomyopathy XII.l XII - Cardiovascular involvement / toxicity
XII.l - Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP) XII.n XII - Cardiovascular involvement / toxicity
XII.n - Cardiovascular collapse - Cardiogenic shock - Hypotension XII.p XII - Cardiovascular involvement / toxicity
XII.p - QTc prolongation XII.t XII - Cardiovascular involvement / toxicity
XII.t - Torsades de pointe XII.af XII - Cardiovascular involvement / toxicity
XII.af - Coronary vasospasm - Vasospastic angina XII.au XII - Cardiovascular involvement / toxicity
XII.au - Heart failure (thyrotoxicosis-, thyroid storm-mediated) XV.a XV - Pathology
XV.a - Path: NSIP-cellular pattern (see also Ia, Ib) XV.b XV - Pathology
XV.b - Path: Eosinophilic pneumonia (subacute or acute) (see also Ic) XV.c XV - Pathology
XV.c - Path: Organizing pneumonia (OP/BOOP) pattern (see also Id) XV.d XV - Pathology
XV.d - Path: Acute fibrinous organizing pneumonia (AFOP-pattern) (see also If) XV.f XV - Pathology
XV.f - Path: Diffuse alveolar damage (DAD-pattern) (see also IL) XV.g XV - Pathology
XV.g - Path: Alveolar hemorrhage (see also IIIa) XV.h XV - Pathology
XV.h - Path: NSIP-fibrotic pattern XV.i XV - Pathology
XV.i - Path: Pneumocyte atypia (reactive epithelial cells) (a.k.a. the "Napoleon Hat" sign) XV.j XV - Pathology
XV.j - Path: Pulmonary fibrosis (UIP-pattern) XV.k XV - Pathology
XV.k - Path: Desquamative interstitial pneumonia (DIP-pattern) XV.m XV - Pathology
XV.m - Path: Lymphoid hyperplasia (including nodular- or a lymphocytic interstitial pneumonia pattern) XV.o XV - Pathology
XV.o - Path: Endogenous lipoid pneumonia (phospholipidosis) XV.r XV - Pathology
XV.r - Path: Smudged geographic necrosis XV.ao XV - Pathology
XV.ao - Path: Pleuritis, pleural fibrosis XV.bt XV - Pathology
XV.bt - Path: Histiocytic proliferation XVI.b XVI - Imaging
XVI.b - Imaging: Ground-glass opacities (GGO) / shadowing XVI.i XVI - Imaging
XVI.i - Imaging: An area or areas of involvement with a recognizable anatomic distribution XVI.j XVI - Imaging
XVI.j - Imaging: Wandering (migratory) pulmonary opacities XVI.n XVI - Imaging
XVI.n - Imaging: Intralobular septal thickening - Crazy paving XVI.s XVI - Imaging
XVI.s - Imaging: An area or areas of involvement with high attenuation numbers or metallic density XVI.w XVI - Imaging
XVI.w - Imaging: Lung nodule or nodules XVI.aa XVI - Imaging
XVI.aa - Imaging: Nodules, mass or masses with a central area of low attenuation (see also under XVIaa) XVI.ab XVI - Imaging
XVI.ab - Imaging: Cavitating/cavitary lung nodule, mass or nodules (see also Iq, XIs, XIIi, XVIaa and XVIIp) XVI.ay XVI - Imaging
XVI.ay - Imaging: Asymmetrical, predominantly unilateral involvement XVI.az XVI - Imaging
XVI.az - Imaging: Solitary pulmonary nodule XVI.bj XVI - Imaging
XVI.bj - Imaging: Atelectasis (a combination of increased density and volume loss. Typically lobar) XVI.bq XVI - Imaging
XVI.bq - Imaging: A pattern consistent with pleuroparenchymal fibroelastosis XVI.bt XVI - Imaging
XVI.bt - Imaging: A subsolid lung nodule or nodules XVI.bx XVI - Imaging
XVI.bx - Imaging: Waxing and waning nodules XVII.e XVII - Infections & related conditions
XVII.e - Pneumocystis jiroveci pneumonia XVIII.b XVIII - Distinctive patterns - 'Eye-catchers'
XVIII.b - Eye catcher: Electron-dense area or areas of consolidation on unenhanced chest CT XVIII.j XVIII - Distinctive patterns - 'Eye-catchers'
XVIII.j - Eye-catcher: Avid lung uptake on 18F-PET-CT XVIII.k XVIII - Distinctive patterns - 'Eye-catchers'
XVIII.k - Eye-catcher: An electron-dense liver on unenhanced CT XVIII.p XVIII - Distinctive patterns - 'Eye-catchers'
XVIII.p - Eye-catcher: An electron-dense ('white') thyroid XIX.a XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.a - BAL: An excess proportion of lymphocytes XIX.b XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.b - BAL: An excess proportion of neutrophils XIX.c XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.c - BAL: An excess proportion of eosinophils XIX.e XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.e - BAL: Stainable iron in macrophages XIX.f XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.f - BAL: Foamy macrophages XIX.m XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.m - BAL: A normal cell differential XIX.p XIX - Cytological, biochemical features of/in BAL, pleural fluid or FNA
XIX.p - BAL: Lamellar bodies in AM on EM
5

Amrinone - Inamrinone

1

Amrubicin

1

Anagrelide

1

Angiotensin converting enzyme inhibitors (ACEI)

I.b I - Interstitial/parenchymal lung disease
I.b - Pneumonitis (ILD) I.c I - Interstitial/parenchymal lung disease
I.c - Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia) IV.a IV - Airway involvement
IV.a - Bronchospasm - Wheezing - Asthma IV.d IV - Airway involvement
IV.d - Cough (lone) IV.f IV - Airway involvement
IV.f - Severe or catastrophic bronchospasm or asthma attack (can be fatal) IV.g IV - Airway involvement
IV.g - Cough syncope V.a V - Pleural and/or pericardial involvement
V.a - Pleural effusion (uni- or bilateral) (can accompany DI-LDs) V.b V - Pleural and/or pericardial involvement
V.b - Eosinophilic pleural effusion V.d V - Pleural and/or pericardial involvement
V.d - Pleural/pericardial effusion, ANA positive (DI lupus) VIII.a VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.a - Angioedema (may cause UAO, asphyxia and death) VIII.q VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.q - Tongue involvement (edema, glossitis, hematoma) VIII.y VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.y - Sinonasal discharge, -blockage, -obstruction VIII.am VIII - Central-large-upper airway (incl. pharyngeal-nasal) involvement
VIII.am - Hemilingual (angio)edema IX.e IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.e - Disordered breathing pattern - Cheynes-Stokes respiration IX.q IX - Neuromuscular / CNS involvement - Disordered breathing during sleep
IX.q - Obstructive sleep apnea X.d X - Systemic/Distant conditions, syndromes and reactions
X.d - Lupus - Lupus syndrome (see also Vd) X.au X - Systemic/Distant conditions, syndromes and reactions
X.au - Visceral angioedema XIII.a XIII - Neoplastic conditions
XIII.a - Lung cancer XVI.bu XVI - Imaging
XVI.bu - Imaging: Upper/central airway narrowing XVIII.f XVIII - Distinctive patterns - 'Eye-catchers'
XVIII.f - Eye-catcher: Tongue edema
1

Antazoline

1

Anthrax vaccination

1

Antibiotics

1

Anticoagulants, direct oral (anti-thrombin, -IIa, -Xa) - NOAC

3

Antidepressants

1

The Pneumotox website uses cookies. By accessing or using our website, you consent to the collection, use and disclosure of the garnered information in accordance with our privacy policy.

Learn more about cookies